Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. (hereinafter referred to as "the company") was established in 1997. It is a modern pharmaceutical enterprise controlled by China Nuclear uranium industry Co., Ltd. and headquartered in Luancheng District, Shijiazhuang. After more than 20 years of development, Dacheng pharmaceutical has two wholly-owned subsidiaries - Hebei Shengxue Dacheng Tangshan Pharmaceutical Co., Ltd. (hereinafter referred to as "Tangshan company") ）、 Hebei Hongcheng Yaxin Technology Co., Ltd. (hereinafter referred to as "Yaxin company"); a holding company - Inner Mongolia Shengxue Dacheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Inner Mongolia company") ）It has four production bases. The company's leading products include oxytetracycline, oxytetracycline hydrochloride, streptomycin sulfate, colistin sulfate, spectinomycin hydrochloride, spectinomycin sulfate, neomycin sulfate, colistin sulfate premix, Streptococcus lactis, etc. it is an important manufacturer of colistin sulfate and streptomycin sulfate at home and abroad, and its production scale ranks in the forefront of the same industry. The company's main products have passed the national GMP certification and EU CEP certification, colistin sulfate has passed the German eu-gmp certification, oxytetracycline series products have passed the U.S. FDA certification, and dihydrostreptomycin has passed the aseptic CEP certification. The company is the only state-owned enterprise in the competition of similar products, with a total production capacity of more than 10000 tons. Its products sell well all over the country and are exported to Europe, America, Southeast Asia, the Middle East, India, North Africa, South America and other dozens of countries and regions, of which colistin sulfate accounts for more than 70% of the global market; Streptomycin sulfate accounts for about 60% of the global market share; Oxytetracycline series products occupy the main international high-end market share. Dacheng pharmaceutical has established long-term strategic cooperative relations with multinational pharmaceutical leaders such as Pfizer, shuotang, Abbott and Cargill. The company has more than 1500 employees, including 853 with college degree or above, 133 with intermediate title and 28 with senior title. The company will firmly establish and implement the new development concept, adhere to the general keynote of transformation and upgrading and high-quality development, center on the development main line of refined products, strengthened technology, and optimized structure, accelerate the industrial layout planning and the progress of mixed reform and listing, and gradually build With equal emphasis on the management and R&D layout of raw materials and preparations, we will build a first-class comprehensive biomedical enterprise in China that is "specialized, refined, and strong".